Epirubicin hydrochloride injection 10 mg in 5 mL (3)

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

epirubicin hydrochloride, Quantity: 2 mg/mL

Disponible depuis:

Pfizer (Perth) Pty Ltd

forme pharmaceutique:

Injection, solution

Composition:

Excipient Ingredients: sodium chloride; hydrochloric acid; water for injections

Mode d'administration:

Intravenous, Intravesical, Intraarterial

Unités en paquet:

5 mL x 1

Type d'ordonnance:

(S1) This Schedule is intentionally blank

indications thérapeutiques:

Farmorubicin has the ability to induce useful responses in a broad spectrum of neoplastic diseases, such as carcinoma of breast, malignant lymphomas, sarcomas of the soft tissues, gastric carcinoma, carcinoma of liver, pancreas, sigmoid rectum, cervico-facial carcinoma, lung carcinoma, ovarian carcinoma and leukemia. High doses of Farmorubicin can be used in the treatment of breast cancer. Positive results have been obtained with Farmorubicin administered intravesically in the treatment of superficial bladder tumors, transitional cells (carcinoma in situ), and in the prophylaxis of recurrences after transurethral resection.

Descriptif du produit:

Visual Identification: Clear and clean red solution.; Container Type: Vial; Container Material: PP; Container Life Time: 36 Months; Container Temperature: Store at 2 to 8 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Statut de autorisation:

Listed (Export Only)

Date de l'autorisation:

2018-09-14